Summary
Background
The economic burden of rotavirus gastroenteritis (RVGE) to society is high as shown from results of recent European studies. The evidence suggests that the implementation of antirotavirus vaccination programs can substantially decrease costs, thus freeing resources for alternative uses. The objective of this study was to measure the health benefits and costs of a pentavalent vaccination program in Italy.
Methods
A decision model was designed to follow a cohort of infants from birth to 5 years of age. Input data were mainly drawn from a recent prospective observational study (REVEAL) conducted in seven European regions, including one in Italy, that recorded healthcare utilization for children under 5 years of age with acute gastroenteritis.
Results
The implementation of a pentavalent antirotavirus vaccination (80% coverage rate) would avoid 61,704 cases of RVGE seeking healthcare; 42,368 GP and paediatricians’ consultations; 38,304 emergency visits; 10,673 hospitalizations; 2327 nosocomial infections; and 7 deaths. It would also avoid 217,596 lost working days for parents. From the national health system perspective, the cost of the program would be €48.5 million and the reduction in the cost of disease would be €20.6 million (−72%). From the societal perspective, the program would reduce the global cost of disease by €56.4 million (−70%) resulting in a net benefit of €7.8 million.
Conclusions
Today prevention is at the top of policy-makers’ agendas in all Western countries. There is a wealth of evidence on the economic and clinical benefits from vaccination programs against RVGE. The present study confirms previous results thus suggesting that the vaccination program should be implemented in Italy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Bibliografia
Kirkwood CD, Buttery J. Rotavirus vaccines — an update. Expert Opin Biol Ther 2003; 3: 97–105
Roberts JA, Cumberland P, Sockett PN, et al. The study of infectious intestinal disease in England: socio-economic impact. Epidemiol Infect 2003; 130: 1–11
Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999; 17: 2207–22
Anderson EJ, Weber SJ. Rotavirus infection in adults. Lancet Infect Dis 2004; 4: 91–9
Clark B, McKendrick M. A review of viral gastroenteritis. Curr Opin Infect Dis 2004; 17: 461–9
Moulin F. Hospitalisations pour gastroentérites aiguës communautaires à rotavirus. Une enquête de quatre ans. Arch Pediatr 2002; 9: 255–61
Ryan MJ, Ramsay M, Brown D, et al. Hospital admissions attributable to rotavirus infection in England and Wales. J Infect Dis 1996; 174 (Suppl. 1): S12–8
Poppe M, Ehlken B, Rohwedder A, et al. Morbidity and hospital admissions due to rotavirus infection in Germany. Monatsschr Kinderheilkd 2002; 150: 491–6
Ruggeri FM, Declich S. Rotavirus infection among children with diarrhoea in Italy. Acta Paediatr Suppl 1999; 88: 66–71
Soriano-Gabarro M, Mrukowics J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006; 25 (1 Suppl.): S7–11
Fontana M, Zuin G, Pancheri P, et al. Costs associated with outpatient diarrhoea in infants and toddlers: a nationwide study of the Italian Society of Paediatric Gastroenterology and Hepatology (SIGEP). Dig Liver Dis 2004; 36: 523–7
Giaquinto C, Callegaro S, Andreola B, et al. Costi della gastroenterite da rotavirus acquisita in comunità in età pediatrica a Padova in Italia. Pharmacoeconomics-Italian Research Articles 2007; 9: 103–11
Lorgelly PK, Joshi D, Iturriza Gómara M, et al. Infantile gastroenteritis in the community: a cost of illness study. Epidemiol Infect 2008; 136: 34–43
Salo H, Ollgren J, Linna M, et al. Economic evaluation of rotavirus vaccination in Finland. 15th Annual EUPHA Meeting. Helsinki, 11–13 October 2007
Huet F, Largeron N, Trichard M, et al. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq® in France. Vaccine 2007; 25: 6348–58
Trichard M. Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination in Spain. 4thHTAi Conference. Barcelona, 16–20 June 2007
Vesikari T, Matson DO, Dennehy P, et al. Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354: 23–33
Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe 2004–2005: the REVEAL study. J Infect Dis 2007; 195 (Suppl. 1): S1–6
Farmindustria. AboutPharma 2008; 37: 34
Marchetti F, Assael B, Gabutti G, et al. Monitoring the rate of hospitalisation before rotavirus immunization in Italy utilising ICD9-CM regional databases. Hum Vaccin 2009; 5: 1–5
Tucker AW, Haddix AC, Bresee JS, et al. Cost-effectiveness analysis of a rotavirus immunization programme for the United States. JAMA 1998; 279: 1371–6
Pharmacoeconomic guidelines around the world. ISPOR. http://www.ispor.org/PEguidelines/COUNTRYSPECIFIC.asp
ISTAT 2004, www.demoistat.it
ISTAT 2005, www.demoistat.it
UNICEF statistics: http://unicef.org/infobycountry/itali.html
Giaquinto C, Van Damme P, Huet F, et al. Clinical impact of rotavirus acute gastroenteritis in Europe 2004–2005: the REVEAL Study. J Infect Dis 2007; 195 (Suppl. 1): S26–35
Gianino P, Mastretta E, Longo P, et al. Incidence of nosocomial rotavirus infections, symptomatic and asymptomatic, in breastfed and non breast-fed infants. J Hosp Infect 2002; 50: 13–7
Beutels P, Bonanni P, Tormans G, et al. An economic evaluation of universal pertussis vaccination in Italy. Vaccine 1999; 18: 2400–9
Gleizes O, Desselberger U, Tatochenko V, et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis J 2006; 25 (1 Suppl.): S12–21
Floret D, Lina B, Pinchinat S, et al. Epidemiology and burden of rotavirus diarrhoea in day care centres in Lyon, France. Eur J Ped 2006; 165: 905–6
Marocco A, Assael B, Gabutti G. Ricoveri per enterite da Rotavirus in Italia valutati mediante analisi delle Schede di Dimissione Ospedaliera negli anni 2001–2003. Ig Sanità Pubbl 2006; 62: 215–24
OECD. Selection of OECD social indicators: how does Italy compare? http://www.oecd.org/dataoecd/35/2/34555477.xls
Banca d’Italia, dicembre 2006.
Lucioni C, Garancini MP, Massi-Benedetti M, et al. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol 2003; 2: 121–33
Coudeville L, Brunot A, Giaquinto C, et al. Varicella vaccination in Italy: an economic evaluation of different scenarios. Pharmacoeconomics 2004; 22: 839–55
Martin A. Standaert B. Cost-effectiveness of infant vaccination with RotarixTM in the UK. 25th Annual Meeting of the European Society for Paediatric Infectious Diseases. Porto, 2–4 May, 2007
Banca d’Italia, 2003.
Pharmacoeconomic guidelines around the world. ISPOR. http://www.ispor.org/PEguidelines/CDKOG8RB7IRF ©VNF DHCSRCKJ,DUM VHTH5JN7D86jxH7S6E76 senyeOUN TRYSPECIFIC.asp
Drummond M, Manca A, Sculpher M. Increasing the generalisability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005; 21: 165–71
Velasco-Garrido M, Busse R. Health Technology Assessment: An introduction to objectives, role of evidence, and structure in Europe. Brussels, Belgium: WHO European Observatory on Health Care Systems, 2005
Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215–8
Lorgelly PK, Joshi D, Iturriza Gómara M, et al. Exploring the cost-effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008: 136: 44–55
Standaert B, Marocco A, Assael B, et al. Analisi di costo-efficacia della vaccinazione universale in Italia con il vaccino Rix4414 contro i rotavirus. Pharmacoeconomics-Italian Research Articles 2008; 10: 23–35
Tarricone R, Torbica A. Hospital cost of central venous catheter-associated blood stream infection (BSI) and cost-effectiveness of closed vs open infusion system. The case of Intensive Care Units in Italy. Annual Congress of the International Federation of Infection Control. Budapest, 19–22 October 2007
Tarricone R. Valutazioni economiche e management in sanità: applicazioni ai programmi e tecnologie sanitarie. Milano: McGraw-Hill, 2004
Griffiths RI, Anderson GF, Powe NR, et al. Economic impact of immunization against rotavirus gastroenteritis: evidence from a clinical trial. Arch Pediatr Adolesc Med 1995; 149: 407–14
Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004; 22: 4203–14
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tarricone, R., Giaquinto, C., Largeron, N. et al. Analisi economica dei costi e dei benefici dell’implementazione di un programma di prevenzione antirotavirus con il vaccino pentavalente in Italia. Pharmacoeconomics-Ital-Res-Articles 11, 1–13 (2009). https://doi.org/10.1007/BF03320653
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03320653